Flow cytometric analysis of U-937 (Human histiocytic lymphoma monocyte, left) / THP-1 (Human monocytic leukemia monocyte, right) were stained with Biotin Mouse IgG1, κ (black) isotype control compared with SDT Biotin Mouse Anti-Human CD135 antibody at 1μl/test (red) followed by Sav-PE and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (blue). Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Negative control: U-937
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD135 |
| Synonyms | Receptor-type tyrosine-protein kinase FLT3; FL cytokine receptor; Fetal liver kinase-2 (FLK-2); Fms-like tyrosine kinase 3 (FLT-3); Stem cell tyrosine kinase 1 (STK-1); FLK2; STK1; FLT3 |
| Location | Membrane |
| Accession | P36888 |
| Clone Number | S-3176 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | THP-1 |
| Purification | Protein G |
| Concentration | 0.1 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1μl per million cells in 100μl volume | Hu |
Background
CD135, also known as FLT3 (Fms-like tyrosine kinase 3), is a class III receptor tyrosine kinase that plays a critical role in the regulation of hematopoiesis by promoting the survival, proliferation, and differentiation of hematopoietic stem and progenitor cells upon binding to its ligand FLT3L; upon activation, CD135 undergoes dimerization and trans-phosphorylation, triggering downstream signaling cascades such as RAS/MAPK and PI3K/AKT pathways, which are essential for lymphoid lineage development and dendritic cell differentiation, while mutations—especially internal tandem duplications (FLT3-ITD)—lead to constitutive kinase activity, contributing to oncogenesis, particularly in acute myeloid leukemia (AML), where it is associated with poor prognosis and targeted by specific kinase inhibitors.
Picture
Picture
FC
